A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers

Jie Zang,Rong Lin,Xuejun Wen,Chao Wang,Tianzhi Zhao,Vivianne Jakobsson,Yun Yang,Xiaoming Wu,Zhide Guo,Xiaoyuan Chen,Jingjing Zhang,Weibing Miao

DOI: https://doi.org/10.1097/rlu.0000000000004820

IF: 10.6

2023-09-16

Clinical Nuclear Medicine

Abstract:In recent decades, remarkable advances have been made in precision medicine based on molecular imaging including PET. 1 Many tumor-targeting radiopharmaceuticals have been developed and consecutively advanced into clinical trials. RGD (Arg-Gly-Asp), a type of cyclic peptide, is a competitive inhibitor of α v β 3 and is used for imaging tumor integrin expression. 2,3 However, RGD-based radiotracers, including multimeric RGD peptides that may improve integrin-targeting efficiency, demonstrated only moderate tumor uptake, 4,5 which may limit its theranostic applications. Lately, PET imaging targeting fibroblast activation protein (FAP), a type II membrane-bound glycoprotein highly expressed in cancer-associated fibroblasts of various types of cancer, has appeared in the international hot frontier. 6 A series of FAP inhibitors (FAPIs) have been developed as imaging agents, including FAPI-02, FAPI-04, and FAPI-46. 7 Quite a few studies have confirmed that FAPI PET/CT is, in many cases, significantly superior to 2- 18 F-FDG PET/CT for diagnosing malignant tumors. 8,9 However, the short tumor retention time of most existing FAPIs makes them unsuitable for radionuclide therapy.

radiology, nuclear medicine & medical imaging